Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
Trial details
- Registry ID
- NCT07362017
- Drugs studied
- Ponesimod
TrialRedline tracks 40 clinical trials sponsored by Vanda Pharmaceuticals: 23 Phase 3, 17 Phase 2.
Company identity has not yet been verified
Names as written in the registry records.
NCT06836557 · Vanda Pharmaceuticals
Before: Estimated. After: Actual.
Before: 100 participants (planned). After: 17 participants (actual).
Before: Estimated. After: Actual.
Before: Dec 2025. After: 30 Mar 2026.
Before: Recruiting. After: Completed.
NCT04652882 · Vanda Pharmaceuticals
Before: Estimated. After: Actual.
Before: 70 participants (planned). After: 43 participants (actual).
Before: Estimated. After: Actual.
Before: Sep 2026. After: 4 Sep 2026.
Before: Active not recruiting. After: Completed.
NCT04652882 · Vanda Pharmaceuticals
Before: Jun 2026. After: Sep 2026.
Before: Recruiting. After: Active not recruiting.
NCT07221578 · Vanda Pharmaceuticals
Before: Recruiting. After: Active not recruiting.
NCT04028492 · Vanda Pharmaceuticals
Before: 992 participants (actual). After: 979 participants (actual).
NCT07362017 · Vanda Pharmaceuticals
Before: Not yet recruiting. After: Recruiting.
NCT07446439 · Vanda Pharmaceuticals
Before: Not yet recruiting. After: Recruiting.
NCT04028492 · Vanda Pharmaceuticals
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change from baseline in daily average nausea severity scores from the Gastroparesis Core Symptom Daily Diary (GCS-DD). After: Measure: Change From Baseline to Week 12 in the Biweekly Average of Daily Nausea Severity Score Using MMRM Model ITT Population.
NCT06138613 · Vanda Pharmaceuticals
Before: 30 May 2026. After: 30 Sep 2027.
NCT05352893 · Vanda Pharmaceuticals
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Proportion of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear). After: Measure: Percentage of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear).
NCT05366855 · Vanda Pharmaceuticals
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Incidence of adverse events. After: Measure: Incidence of Adverse Events.
Before: 8 Feb 2024. After: 12 Jul 2024.
NCT05352893 · Vanda Pharmaceuticals
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Proportion of subjects achieving Generalized Pustular Psoriasis Physician's Global Assessment (GPPPGA) score of 0 (clear) or 1 (almost clear). After: Measure: Proportion of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear).
NCT07065773 · Vanda Pharmaceuticals
Before: Mar 2026. After: Sep 2026.
Before: Recruiting. After: Active not recruiting.
NCT07090161 · Vanda Pharmaceuticals
Before: Not yet recruiting. After: Recruiting.
NCT04652882 · Vanda Pharmaceuticals
Before: Dec 2025. After: Jun 2026.